PT  - JOURNAL ARTICLE
AU  - Ana Lucía Figueredo Cacacho
AU  - José Ángel Carretero Gracia
AU  - Dinora Polanco Alonso
AU  - Clara Viñado Mañes
AU  - Carolina Panadero Paz
AU  - Sandra García Saez
AU  - Sara Gomara
AU  - Erica León
AU  - Ana Lilian Simón Robles
AU  - Enrique Chacón Valles
AU  - Salvador Bello Dronda
TI  - Experience with omalizumab in patients with moderate and severe asthma
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P2429
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P2429.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P2429.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - OBJETIVESTo describe the outcome of patients treated with Omalizumab -OMZ- for at least 16 weeks.METHODSA prospective study of asthmatic patients under treatment with OMZ in the sanitary area of the University Hospital Miguel Servet of Saragossa since 2006. The efficacy variables studied: ACT (-Asthma Control Test-), daily dose of corticosteroids (oral -OC- and inhaled -IC-), acute exacerbations and hospital admissions.RESULTSSince 2006 we had begun OMZ in 40 patients, with a mean age of 49.2 (16.4 SD) years, 87.5% were women. By october 2013, 28 patients continued OMZ, 4 were excluded (less than 4 months of treatment).The mean FEV1 (%pred) went from 72 (23.6 SD) to 81% (20.6 SD) after OMZ. The mean ACT went from 15 to 19 points after OMZ. A controlled asthma was achieved in 46% of patients, and the non controlled asthma patients went from 67 to 29%A reduction of total IC was of 32%. 8 patients required daily OC, after OMZ only 2 needed OC but in less doses.We noticed a 72% reduction of annual asthmatic exacerbations, and this result was kept during the treatment. Before OMZ, 53% of the patients had at least one hospital admission in the previous 4 years. With OMZ this number reduced to 9%.CONCLUSIONSOMZ achieved an improvement in the asthma control level, reduced the number of exacerbations and hospital admissions, and the requirement of corticosteroids. This improvement was not relevant in the pulmonary function (FEV1 pred).